Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of Lefamulin IR Tablet vs IV and Capsule
NCT02557789Phase 1Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Jun 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lefamulin in community-acquired bacterial pneumonia (CAP) (4 arms), sponsored by Nabriva Therapeutics plc. Primary endpoint: Area under the concentration time curve (AUC) of an intravenous and oral formulation of lefamulin in the fasting state at 36 hours. Started Jun 2015; status: completed.
02
Drugs
lefamulin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02557789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557789.